ATE355844T1 - Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend - Google Patents

Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend

Info

Publication number: ATE355844T1
Authority: AT; Austria
Prior art keywords: norethisterone; testosterone; composition; male contraception; testosterone undecanoate
Prior art date: 2000-02-15

Application number

AT01902590T

Other languages

English (en)

Inventor

Eberhard Nieschlag

Axel Kamischke

Michael Oettel

Alexander Ruebig

Ekkerhard Schillinger

Ursula-Friederike Habenicht

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2001-02-15

Publication date

2007-03-15

2001-02-15 Application filed by Schering Ag filed Critical Schering Ag

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE355844T1 publication Critical patent/ATE355844T1/de

Links

239000000203 mixture Substances 0.000 title abstract 4
229940053934 norethindrone Drugs 0.000 title abstract 3
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 title abstract 3
UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 title abstract 2
229960000746 testosterone undecanoate Drugs 0.000 title abstract 2
238000009472 formulation Methods 0.000 abstract 3
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
206010003883 azoospermia Diseases 0.000 abstract 2
239000000583 progesterone congener Substances 0.000 abstract 2
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 abstract 1
APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 abstract 1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 1
239000003098 androgen Substances 0.000 abstract 1
230000001548 androgenic effect Effects 0.000 abstract 1
230000001076 estrogenic effect Effects 0.000 abstract 1
239000002583 male contraceptive agent Substances 0.000 abstract 1
229960001652 norethindrone acetate Drugs 0.000 abstract 1
229960002082 norethindrone enanthate Drugs 0.000 abstract 1
208000008634 oligospermia Diseases 0.000 abstract 1
230000021595 spermatogenesis Effects 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1
229960003604 testosterone Drugs 0.000 abstract 1
-1 testosterone ester Chemical class 0.000 abstract 1
150000003515 testosterones Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Orthopedics, Nursing, And Contraception (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

AT01902590T 2000-02-15 2001-02-15 Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend ATE355844T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50372900A	2000-02-15	2000-02-15
EP00200493		2000-02-15

Publications (1)

Publication Number	Publication Date
ATE355844T1 true ATE355844T1 (de)	2007-03-15

Family

ID=26071832

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06075322T ATE474580T1 (de)	2000-02-15	2001-02-15	Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend
AT01902590T ATE355844T1 (de)	2000-02-15	2001-02-15	Zusammensetzung zur männlichen kontrazeption, norethisteron und testosteron undecanoat enthaltend

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT06075322T ATE474580T1 (de)	2000-02-15	2001-02-15	Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend

Country Status (26)

Country	Link
EP (2)	EP1666044B1 (de)
JP (1)	JP2003522795A (de)
KR (1)	KR20020086905A (de)
CN (1)	CN1423560A (de)
AT (2)	ATE474580T1 (de)
AU (1)	AU2001230447A1 (de)
BG (1)	BG107066A (de)
BR (1)	BR0108411A (de)
CA (1)	CA2398063A1 (de)
CY (1)	CY1106639T1 (de)
CZ (1)	CZ20022691A3 (de)
DE (2)	DE60142647D1 (de)
DK (1)	DK1267885T3 (de)
EE (1)	EE200200454A (de)
ES (1)	ES2282230T3 (de)
HK (1)	HK1049442B (de)
HU (1)	HUP0300128A3 (de)
IL (1)	IL151219A0 (de)
MX (1)	MXPA02007675A (de)
NO (1)	NO20023607L (de)
PL (1)	PL357185A1 (de)
PT (1)	PT1267885E (de)
RU (1)	RU2002124602A (de)
SI (1)	SI1267885T1 (de)
SK (1)	SK11602002A3 (de)
WO (1)	WO2001060376A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10234525A1 (de) *	2002-07-25	2004-02-05	Schering Ag	Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
TW200404552A (en) *	2002-05-30	2004-04-01	Akzo Nobel Nv	Self administered contraception
PL373808A1 (en)	2002-07-24	2005-09-19	Schering Aktiengesellschaft	Microbiological method for the production of 7 alpha-substituted 11 alpha-hydroxysteroids
EP1524983B1 (de) *	2002-07-25	2008-01-02	Bayer Schering Pharma Aktiengesellschaft	Zusammensetzung, enthaltend ein androgenes 11-b-halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung
JO2505B1 (en) *	2003-03-14	2009-10-05	باير شيرنغ فارما اكتنجيسيلشافت	Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
CN101352443B (zh) *	2007-07-23	2011-01-12	中国科学院动物研究所	哺乳动物雄性不育剂
EP3750538B1 (de)	2018-03-23	2024-08-14	Pharmajor International	Nicht-hormonelle verfahren zur männlichen kontrazeption enthaltend (r)-silodosin
WO2025198399A1 (ko) *	2024-03-22	2025-09-25	주식회사 에아스텍	노르에티스테론 에난테이트 화합물의 암의 예방 또는 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2714420A1 (de) *	1976-06-01	1977-12-08	Int Pregnancy Advisory Service	Antikonzeptionsmittel zur verabreichung an mann und frau in einer gemeinsamen verabreichungspackung
US4210644A (en)	1978-02-23	1980-07-01	The Johns Hopkins University	Male contraception
US5035891A (en)	1987-10-05	1991-07-30	Syntex (U.S.A.) Inc.	Controlled release subcutaneous implant
CN1102095A (zh) *	1993-10-30	1995-05-03	浙江医科大学	长效雄激素类制剂——十一酸睾丸注射液
DE19650352A1 (de) *	1996-12-04	1998-07-30	Jenapharm Gmbh	Oral wirksames Kombinationspräparat zur Kontrazeption für den Mann

2001
- 2001-02-15 AT AT06075322T patent/ATE474580T1/de not_active IP Right Cessation
- 2001-02-15 CA CA002398063A patent/CA2398063A1/en not_active Abandoned
- 2001-02-15 PT PT01902590T patent/PT1267885E/pt unknown
- 2001-02-15 RU RU2002124602/15A patent/RU2002124602A/ru not_active Application Discontinuation
- 2001-02-15 ES ES01902590T patent/ES2282230T3/es not_active Expired - Lifetime
- 2001-02-15 MX MXPA02007675A patent/MXPA02007675A/es unknown
- 2001-02-15 EP EP06075322A patent/EP1666044B1/de not_active Expired - Lifetime
- 2001-02-15 DK DK01902590T patent/DK1267885T3/da active
- 2001-02-15 SI SI200130726T patent/SI1267885T1/sl unknown
- 2001-02-15 CZ CZ20022691A patent/CZ20022691A3/cs unknown
- 2001-02-15 PL PL01357185A patent/PL357185A1/xx not_active Application Discontinuation
- 2001-02-15 AU AU2001230447A patent/AU2001230447A1/en not_active Abandoned
- 2001-02-15 SK SK1160-2002A patent/SK11602002A3/sk unknown
- 2001-02-15 BR BR0108411-9A patent/BR0108411A/pt not_active IP Right Cessation
- 2001-02-15 HU HU0300128A patent/HUP0300128A3/hu unknown
- 2001-02-15 WO PCT/IB2001/000188 patent/WO2001060376A1/en not_active Ceased
- 2001-02-15 JP JP2001559472A patent/JP2003522795A/ja active Pending
- 2001-02-15 EE EEP200200454A patent/EE200200454A/xx unknown
- 2001-02-15 EP EP01902590A patent/EP1267885B8/de not_active Expired - Lifetime
- 2001-02-15 IL IL15121901A patent/IL151219A0/xx unknown
- 2001-02-15 HK HK03101578.5A patent/HK1049442B/en not_active IP Right Cessation
- 2001-02-15 DE DE60142647T patent/DE60142647D1/de not_active Expired - Lifetime
- 2001-02-15 AT AT01902590T patent/ATE355844T1/de active
- 2001-02-15 DE DE60127103T patent/DE60127103T2/de not_active Expired - Lifetime
- 2001-02-15 KR KR1020027010715A patent/KR20020086905A/ko not_active Withdrawn
- 2001-02-15 CN CN01808041A patent/CN1423560A/zh active Pending
2002
- 2002-07-30 NO NO20023607A patent/NO20023607L/no not_active Application Discontinuation
- 2002-09-05 BG BG107066A patent/BG107066A/xx unknown
2007
- 2007-06-05 CY CY20071100743T patent/CY1106639T1/el unknown

Also Published As

Publication number	Publication date
IL151219A0 (en)	2003-04-10
WO2001060376A1 (en)	2001-08-23
KR20020086905A (ko)	2002-11-20
AU2001230447A1 (en)	2001-08-27
SI1267885T1 (sl)	2007-08-31
CN1423560A (zh)	2003-06-11
ATE474580T1 (de)	2010-08-15
BG107066A (en)	2003-05-30
EP1666044B1 (de)	2010-07-21
CY1106639T1 (el)	2012-01-25
EE200200454A (et)	2003-12-15
NO20023607D0 (no)	2002-07-30
HK1049442B (en)	2007-06-15
CA2398063A1 (en)	2001-08-23
HUP0300128A2 (en)	2003-05-28
EP1267885B1 (de)	2007-03-07
JP2003522795A (ja)	2003-07-29
ES2282230T3 (es)	2007-10-16
MXPA02007675A (es)	2004-02-26
SK11602002A3 (sk)	2003-03-04
HUP0300128A3 (en)	2004-03-29
PT1267885E (pt)	2007-05-31
DE60127103T2 (de)	2007-11-22
BR0108411A (pt)	2003-03-11
EP1666044A1 (de)	2006-06-07
DE60127103D1 (de)	2007-04-19
DE60142647D1 (de)	2010-09-02
NO20023607L (no)	2002-10-15
PL357185A1 (en)	2004-07-26
EP1267885B8 (de)	2007-06-20
RU2002124602A (ru)	2004-03-10
EP1267885A1 (de)	2003-01-02
CZ20022691A3 (cs)	2003-01-15
DK1267885T3 (da)	2007-07-09
HK1049442A1 (en)	2003-05-16

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1267885

Country of ref document: EP

Publication	Publication Date	Title
CY1106639T1 (el)	2012-01-25	Τυποποιηση αντισυλληπτικου για ανδρες που περιλαμβανει νορεθιστερονη
RU99118582A (ru)	2001-06-10	Композиция для чрескожного введения стероидных лекарственных средств
HK1056181A1 (zh)	2004-02-06	作為抗炎劑的17β-硫代羧酸酯17α-芳基羰氧基氧雄甾烷衍生物
NO20032805D0 (no)	2003-06-19	Preparater av östrogensyklodekstrinkomplekser
CA2084891A1 (en)	1992-10-13	Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders
KR960704553A (ko)	1996-10-09	적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen)
AR073972A2 (es)	2010-12-15	Composiciones farmaceuticas para el tratamiento de carencias estrogenicas en la menopausia y para la prevencion de la osteoporosis en mujeres menopausicas
WO2001003687A3 (en)	2001-08-09	Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans
DE122007000011I1 (de)	2007-05-10	Feste Arzneiformen, enthaltend Clathrate vom steroidalen Sexualhormon Ethinylestradiol
NO884230D0 (no)	1988-09-23	Antikonsepsjonelt preparat.
BR0113376A (pt)	2003-07-15	Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina
CA2467237A1 (en)	2003-05-22	Method of preventing or treating benign gynaecological disorders
WO2004006936A8 (en)	2005-03-03	Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
RU2001101892A (ru)	2003-01-27	Производное тестостерона
DE59805902D1 (de)	2002-11-14	Nichtestrogene derivate des estradiols mit antioxidativer aktivität
WO2001040255A3 (en)	2001-11-15	14,15-beta-methylene substituted androgens
AU1967300A (en)	2000-06-13	Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
MXPA05010871A (es)	2005-11-25	Metodos para administrar estrogenos y progestinas.
JP2003522795A5 (de)	2008-03-06
AR027526A1 (es)	2003-04-02	Formulacion anticonceptiva masculina que comprende noretisterona
JP2005532336A (ja)	2005-10-27	新規なエトノゲストレルエステルの使用
CR6627A (es)	2008-06-18	Nuevo medicamento contraceptivo y su modo de preparacion
IE34308L (en)	1970-12-16	11ß, 13ß-DIALKYLGONA-1,3,5(10)-TRIEN-3-OL 3-CYCLOALKYL¹ETHERS
WO2003032924A3 (en)	2004-01-29	Novel tibolone formulations
PL360669A1 (en)	2004-09-20	4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds